Home/Filings/4/0001209191-14-016908
4//SEC Filing

Endo International plc 4

Accession 0001209191-14-016908

CIK 0001593034operating

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 6:45 PM ET

Size

21.6 KB

Accession

0001209191-14-016908

Insider Transaction Report

Form 4
Period: 2014-02-28
DE SILVA RAJIV
DirectorPresident & CEO
Transactions
  • Award

    Ordinary Shares

    2014-02-28+164,921164,921 total
  • Award

    2010 Stock Incentive Plan Performance Shares

    2014-02-28+82,18282,182 total
  • Award

    2010 Stock Incentive Plan Performance Shares

    2014-02-28+82,18282,182 total
  • Award

    2010 Stock Incentive Plan Stock Options (NQ)

    2014-02-28+135,899135,899 total
    Exercise: $30.42Exp: 2023-03-18Ordinary Shares (135,899 underlying)
  • Award

    Ordinary Shares

    2014-02-28+63,31563,315 total(indirect: By Trust)
  • Award

    2010 Stock Incentive Plan Restricted Stock Units (RSU)

    2014-02-28+27,39427,394 total
Footnotes (6)
  • [F1]On February 28, 2014, Endo Health Solutions, Inc. ("Endo") and Paladin Laboratories Inc. ("Paladin") consummated a transaction under an arrangement agreement pursuant to which each of Endo and Paladin was acquired by a new Irish holding company, Endo International plc ("New Endo"). Under the terms of the arrangement agreement (a) New Endo acquired Paladin pursuant to a plan of arrangement under Canadian law and (b) a newly formed subsidiary of New Endo merged with and into Endo, with Endo as the surviving corporation in the merger (the "Merger") and an indirect wholly owned subsidiary of New Endo. At the effective time of the Merger, each Endo common share was cancelled and converted into the right to receive one New Endo ordinary share. The number here represents shares of New Endo acquired pursuant to the Merger.
  • [F2]These indirectly owned common shares, representing shares of common stock held in trusts, were also acquired pursuant to the Merger and each share was converted into the right to receive one New Endo ordinary share.
  • [F3]These restricted stock units granted on March 18, 2013 under the 2010 Stock Incentive Plan, of which 13,697 were already vested as of February 28, 2014 with the unvested portion generally vesting 33-1/3% annually on each of December 31, 2014 and March 18, 2016, were assumed by New Endo in the Merger and converted into New Endo restricted stock units with the same terms and conditions as the original Endo restricted stock units.
  • [F4]These performance share units granted on March 18, 2013 under the 2010 Stock Incentive Plan were assumed by New Endo in the Merger and converted into New Endo performance share units with the same terms and conditions as the original Endo performance share units. These performance shares vest on December 31, 2015 upon the Company achieving certain shareholder return targets over the period beginning on January 1, 2013 and ending on December 31, 2015. The amount of performance share units included in this line represents the target quantity of shares issuable. The exact number of shares issuable, between 0% and 300% of the target shares, will be based on achievement, as determined by the Compensation Committee of the Board of Directors of Endo, of the specified shareholder return targets over the cumulative 3-year period set forth above.
  • [F5]These performance share units granted on March 18, 2013 under the 2010 Stock Incentive Plan were assumed by New Endo in the Merger and converted into New Endo performance share units with the same terms and conditions as the original Endo performance share units. These performance shares vest on March 18, 2016 upon the Company achieving certain shareholder return targets over the period beginning on March 18, 2013 and ending on March 18, 2016 (or earlier upon certain circumstances). The amount of performance share units included in this line represents the target quantity of shares issuable. The exact number of shares issuable, between 0% and 150% of the target shares, will be based on achievement, as determined by the Compensation Committee of the Board of Directors of Endo, of the specified shareholder return targets over the cumulative 3-year period set forth above. Mr. De Silva shall retain ownership of the shares issued from these performance shares for two years after delivery.
  • [F6]These non-qualified stock options granted on March 18, 2013 under the 2010 Stock Incentive Plan, of which 45,299 were already vested as of February 28, 2014 with the unvested portion generally vesting 33-1/3% per year on each of December 31, 2014 and December 31, 2015, were assumed by New Endo in the Merger and converted into options to purchase ordinary shares of New Endo for the listed exercise price per share with the same terms and conditions as the original Endo stock options.

Issuer

Endo International plc

CIK 0001593034

Entity typeoperating

Related Parties

1
  • filerCIK 0001593034

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 6:45 PM ET
Size
21.6 KB